Although an important contribution of ERK and JNK mitogen-activated protein kinase (MAPK) activation in Ras transformation of rodent ®broblasts has been determined, their role in mediating oncogenic Ras transformation of human tumor cells remains to be established. We have utilized the human HT1080 ®brosarcoma and DLD-1 colon carcinoma cell lines, which contain endogenous mutated and oncogenic N-and K-ras alleles, respectively, to address this role. Study of these cells is advantageous over Ras-transformed rodent model cell systems for two key reasons. First, the ras mutations occurred naturally in the progression of the tumors from which the cell lines were derived, rather than due to overexpression of an exogenously introduced gene. Second, although these tumor cells possess defects in multiple genetic loci, it has been established that mutated Ras contributes signi®cantly to the transformed phenotype of these cells. Clonal variant lines of HT1080 and DLD-1 have been isolated which have lost the oncogenic ras allele and exhibit a corresponding impairment in growth transformation in vitro and in vivo. We found that upregulation of Raf/MEK/ERK and JNK correlated with expression of oncogenic Ras in HT1080, but not DLD-1 cells. Furthermore, inhibition of ERK activation in parental HT1080 cells caused the same changes in cell morphology and actin stress ®ber organization seen with loss of expression of activated NRas(61K). Thus, we suggest that constitutive activation of the Raf/MEK/ERK and JNK pathways is necessary for Ras-induced transformation of HT1080 but not DLD-1 cells. These results emphasize that cell type dierences exist in the signaling pathways by which oncogenic Ras causes transformation.
Introduction
The association of mutated ras (H-, K-and N-ras) genes in 30% of all human cancers suggests an important contribution of aberrant Ras function to the development of human cancers (Barbacid, 1987; Bos, 1989; Clark and Der, 1993) . Such a role is supported by experimental overexpression of mutated Ras proteins in cell culture-based and transgenic animal model systems. For example, overexpression of exogenously-introduced mutated ras genes has been shown to cause potent morphologic and growth transformation of a variety of rodent ®broblast and epithelial cell lines. Oncogenic ras can cooperate with other oncogenes to cause transformation of a variety of primary cells. Finally, the enhanced tumorigenesis seen in transgenic mice harboring mutated ras genes, also supports a key role of Ras in human carcinogenesis.
Since human cancers arise as a consequence of mutations in multiple genetic loci, the precise contribution of mutated ras to the malignant growth phenotype of human cancers remains to be fully elucidated. However, two studies of human tumor cells provide evidence that mutated ras genes contribute signi®cantly to the aberrant growth properties of human tumor cells. First, Shirasawa et al. (1993) utilized homologous recombination to isolate variants of the DLD-1 and HCT116 human colon carcinoma cell lines that had lost the mutated K-ras allele. Loss of mutated ras caused a dramatic impairment in growth in vitro (e.g., colony formation in soft agar) and in tumor formation in nude mice. Second, we have shown that a variant of the HT1080 human ®brosarcoma cell line (designated MCH603c8), that had lost the short arm of chromosome one harboring the mutated N-ras allele (Anderson et al., 1994) , corresponded to a signi®cant impairment in its ability to grow in soft agar and to form tumors in nude mice (Plattner et al., 1996) . This deletion occurred serendipitously during the microcell transfer of a copy of chromosome 1 from HT1080 cells that contained the wild type allele of N-ras into recipient HT1080 cells, i.e. the p-arm deletion occurred in the endogenous chromosome 1 containing the mutant allele. In those cells that received an intact chromosome 1 and retained the mutant N-ras allele, there was no change in their transformed or tumorigenic phenotypes (Anderson et al., 1994) . Reintroduction of mutated N-ras into MCH603c8 resulted in a restoration of these growth properties.
Taken together, these studies clearly demonstrate that mutated ras contributes signi®cantly to the transformed and tumorigenic growth properties of at least some human tumor cells.
The three human ras genes encode four Ras proteins that function as GDP/GTP-regulated binary switches (Boguski and McCormick, 1993) . Ras proteins reside at the inner surface of the plasma membrane where they relay signals initiated by a wide variety of extracellular stimuli that control normal cell growth and dierentiation to cytoplasmic signaling molecules (Egan and Weinberg, 1993; Khosravi-Far et al., 1998; Marshall, 1995) . Upon stimulation, a rapid increase in the ratio of active, Ras-GTP occurs. This active state is transient and GTPase activating proteins (GAPs) stimulate conversion of Ras back to an inactive, GDP-bound state. Mutated ras genes encode oncogenic Ras proteins that contain single amino acid substitutions primarily at residues 12, 13 or 61 that render Ras insensitive to the action of Ras GAPs. Consequently, these mutant proteins persist as constitutively active, GTP-complexed proteins that cause chronic activation of growth-regulatory signaling pathways.
Ras mediates its actions through interaction with downstream eector targets that preferentially associate with active Ras-GTP (Khosravi-Far et al., 1998; Marshall, 1996) . Considerable evidence supports the role of the Raf-1 serine/threonine kinase as a key eector of Ras function. Activated Ras-GTP causes activation of Raf-1, in part, by causing translocation of the normally cytosolic Raf-1 protein to the plasma membrane (Leevers et al., 1994; Stokoe et al., 1994) , where a poorly understood series of events are initiated that cause full Raf-1 activation (Morrison and Cutler, 1997) . Activated Raf then causes activation of the mitogen-activated protein kinase (MAPK) kinases MEK1 and MEK2, which in turn cause activation of the p42 and p44 MAPKs (also known as ERK2 and ERK1, respectively). Activated ERKs translocate into the nucleus where they phosphorylate and activate a variety of targets that include the Elk-1 transcription factor (Marais et al., 1993) . Elk-1 causes transcriptional activation of a variety of growth-regulatory genes that include the cfos proto-oncogene.
The importance of the Raf/MEK/ERK kinase cascade in mediating Ras transformation has been demonstrated in NIH3T3 mouse ®broblasts. The ability of dominant negative mutants of Raf, MEK or ERK to block Ras transformation demonstrates that activation of this cascade is necessary for transformation (Brtva et al., 1995; Cowley et al., 1994; Kolch et al., 1991; Meloche et al., 1992; Troppmair et al., 1994; Westwick et al., 1994) . The ability of constitutively activated mutants of Raf-1 or MEK to cause morphologic and growth transformation of NIH3T3 cells shows that activation of this pathway alone is sucient to promote Ras transformation (Cowley et al., 1994; Mansour et al., 1994; Stokoe et al., 1994) . However, recent observations revealed a more complex scenario where Ras causes transformation by activation of multiple eectors in addition to the three Raf kinases (Khosravi-Far et al., 1998; Marshall, 1996) . First, it was shown that eector domain mutants of Ras that no longer bind Raf can still cause tumorigenic transformation of NIH3T3 cells (Khosravi-Far et al., 1996; White et al., 1995) . Second, we observed that Ras transformation of RIE-1 and other epithelial cells required both activation of Rafdependent and Raf-independent pathways (Gangarosa et al., 1997; Oldham et al., 1996 Oldham et al., , 1998 . Third, Ras causes activation of a Raf-independent MAPK cascade that leads to activation of the Jun NH 2 -terminal kinases (JNKs) (Minden et al., 1994; Olson et al., 1995) and inhibition of JNK activation also inhibits Ras transformation of NIH3T3 cells (Clark et al., 1997) . Finally, the roster of candidate Ras eectors continues to grow and includes a diverse spectrum of proteins that show preferential binding to Ras-GTP (Khosravi-Far et al., 1998; Marshall, 1996) . These include members of the family of phosphatidylinositol 3-kinase (PI3K) lipid kinases (Chantry et al., 1997 , Rodriguez-Viciana et al., 1994 , activators of the Rasrelated Ral proteins (RalGDS, RGL, RGL2/Rlf) (Hofer et al., 1994; Kikuchi et al., 1994; Peterson et al., 1996; Spaargaren and Bischo, 1994; Wolthuis et al., 1996) , Ras GAPs (Boguski and McCormick, 1993) , Rin1 (Han and Colicelli, 1995) , and AF6 (Kuriyama et al., 1996; Van Aelst et al., 1994) . Therefore, the precise contribution of the Raf/MEK/ERK pathway to Ras transformation of human tumor cells remains unresolved.
An emerging theme in signal transduction is that speci®c signaling molecules are likely to have distinct, cell type-speci®c functions (Khosravi-Far et al., 1998) . ras mutations are most prevalent in epithelial cellderived human carcinomas (Bos, 1989; Clark and Der, 1993) . Thus, caution must be exercised in extrapolating observations made in the study of Ras transformation in experimental rodent ®broblast cell systems to human cancer cells. Furthermore, the relative ease in which rodent cells can be transformed contrasts dramatically with the highly resistant nature of human cells to transformation. Therefore, we have chosen to evaluate the role of MAPKs in Ras transformation utilizing two human tumor cell systems. As described above, it has been demonstrated that mutated ras is important for growth transformation of both HT1080 human ®brosarcomas and DLD-1 colon carcinoma cells. A valid criticism of experimental studies in rodent cell systems is that overexpression of an exogenously introduced mutated ras gene is used to cause transformation (Hua et al., 1997) . The mutated N-ras(61K) and K-ras(13D) alleles present in HT1080 and DLD-1 cells, respectively, arose during the natural development of these tumor cells (Plattner et al., 1996; Shirasawa et al., 1993) . The availability of variants of HT1080 and DLD-1 cells, that have lost their mutated ras alleles, allows for a comparative analysis to determine the signaling pathways that are activated by oncogenic Ras to cause tumorigenic transformation of these cells. In the present study, we found that constitutive activation of MAPKs correlated with the expression of oncogenic Ras in HT1080, but not DLD-1, cells. Furthermore, we found that inhibition of ERK activation in HT1080 cells caused the same reversion seen when the mutated N-ras allele is lost from these cells. We suggest that upregulated activation of MAPKs may be critical for Ras transformation of HT1080 but not DLD-1 cells. As we and others have described previously (Khosravi-Far et al., 1995) , untransformed NIH3T3 cells do not exhibit detectable levels of activated ERKs, whereas H-Ras(61L)-transformed NIH3T3 cells show high levels of activated p42 ERK2 or p44 ERK1 (Figure 1) . Similar results were seen in both the mobility shift ( Figure 1a ) and the activated ERK (Figure 1b) analyses. We observed that the parental HT1080 (6TG) cell line, which contains an oncogenic N-ras(61K) allele, possessed a 2.9-fold higher level of activated ERKs, when compared to the HT1080 variant (MCH 603c8) that had lost the mutated Nras sequence (Figure 1a ,b and c). This activation was due to activation of p42 ERK2, whereas no detectable activated p44 ERK1 was seen. However, transient activation of ERKs was seen in these cells when treated with EGF (Figure 1c ), indicating that these cells were not defective in the signaling pathways that involve Ras activation of ERKs. Finally, isolates of MCH603c8 where we had re-established expression of mutant N-Ras(61K) (M8-10 and M5-8) (35) regained high levels of activated p42 ERK2 and p44 ERK1 that correlated with the low (M8-10) or high (M5-8) levels of N-Ras(61K) expression (2.4-and 4.7-fold, respectively) (Figure 1a ,b). We conclude that constitutive upregulation of ERKs is associated with the expression of activated N-Ras in HT1080 cells.
Results

Oncogenic
We next determined whether constitutive ERK activation was associated with expression of mutated K-Ras(13D) in DLD-1 cells. The parental DLD-1 cell line, which contains one wild type and one mutated (13D) K-ras allele, was compared to knockout variants that had lost either the wild type (DKO1) or mutant allele (DKO3 and DKs8) (Shirasawa et al., 1993) . Dks5 is a variant that was isolated during the homologous knockout procedure that retains both wild type and mutant K-ras alleles. Unlike the HT1080-derived cell lines, we observed no correlation between the presence of activated Ras and the level of ERK activation ( Figure 1c) . Clones that contained a disrupted mutant K-ras allele (DK03 and DKs8) showed similar levels of activated ERK2 as the parental DLD-1 cell line or as DLD-1 variant cell lines that retained the mutated Kras allele (DK01 and DKs5) ( Figure 1c ). Immunoblots, using the antibody that recognizes only the phosphorylated forms of the ERKs, also showed comparable low levels in the parental DLD-1 and knockout clones (data not shown). An ERK immune complex kinase assay showed that all DLD-1 cell lines had similar Figure 1 Constitutive activation of p42 and p44 ERKs correlates with expression of oncogenic Ras in HT1080, but not DLD-1, human tumor cells. ERK activity was assayed by Western blot analyses using (a and c) an ERK1/2-speci®c antibody or (b) a phospho-ERK antibody, or (d) by in vitro kinase assay. Arrows denote phosphorylated forms of ERK1 (p44) and ERK2 (p42) levels of ERK activity, whereas HT1080 had 2.1-fold higher activity than MCH 603c8 (Figure 1d ). Therefore, constitutive activation of ERKs did not correlate with oncogenic Ras expression in DLD-1 cells.
One possible explanation for the lack of ERK upregulation in cells expressing mutated K-Ras(13D) may be that these DLD-1 variant cell lines are impaired in the signaling components that link Ras with ERKs. To address this possibility, we stimulated serum-starved DLD-1 cells with epidermal growth factor (EGF), which is known to activate the Ras/ ERK pathway. The parental DLD-1 and the KRas(13D)-de®cient cell lines (DKO3 and DKs8) showed similar ecient stimulation of ERKs by EGF treatment (2.3 ± 4.5-fold) ( Figure 1c ). Thus, we believe that the Ras/ERK pathway is intact in DLD-1 cells.
Elevated Raf-1 and MEK1 kinase activity are associated with the expression of oncogenic N-Ras(61K) in HT1080 ®brosarcoma cells Since ERKs can be activated by signaling pathways independent of the Ras/Raf pathways, we performed Raf and MEK kinase assays in order to determine whether constitutive activation of Raf and MEK also correlated with the expression of mutated N-Ras(61K) in HT1080 cells. For these analyses, we immunoprecipitated endogenous Raf-1 and MEK1 from serumstarved cultures of the various HT1080 cell lines. The Raf-1 kinase assay was carried out using a coupled assay with recombinant MEK as an intermediate and kinase-de®cient ERK protein as a substrate. The MEK assay utilized kinase-de®cient ERK as a substrate.
Whereas MCH603c8 showed low Raf-1 and MEK1 kinase activities, the parental HT1080 cells contained high levels (twofold) of both kinases ( Figure 2 ). In contrast, stable transfectants of MCH603c8, which expressed large amounts of exogenously introduced NRas(61K), possessed approximately threefold higher levels of Raf-1 and MEK1 kinase activity. Therefore, expression of oncogenic N-Ras(61K) correlated with elevated Raf, MEK, and ERK kinase activity in the HT1080-derived cell lines. Thus, ERK activation is likely due to oncogenic Ras upregulation of the Raf/ MEK pathway.
Upregulation of the JNK MAPK is associated with expression of oncogenic Ras in HT1080 but not DLD-1 cells
In addition to ERKs, oncogenic Ras has been shown to cause constitutive activation of the JNKs in NIH3T3 cells (Khosravi-Far et al., 1996) . JNK activation has also been shown to be required for Ras transformation of NIH3T3 cells (Clark et al., 1997) . Therefore, we were interested in determining whether the JNK cascade was constitutively activated in human tumor cell lines containing mutant N-or Kras alleles. For these analyses, endogenous JNK was immunoprecipitated from the dierent HT1080 and DLD-1 cell lines for use in an in vitro JNK kinase assay using recombinant GST-Jun as a substrate. Equal amounts of JNK protein were immunoprecipitated for each sample as assessed by immunoprecipitation and Western blotting (data not shown). Similar to ERK, we observed that elevated JNK activity also correlated with expression of N-Ras(61K) in HT1080 cells. The parental HT1080 cell line, as well as the variants of 603c8 with reconstituted N-Ras(61K) expression (M5-8, M8-10 and M8-17), all exhibited JNK activities that were elevated (2.0 ± 2.6-fold) when compared to MCH603c8 cells (Figure 3a) . In contrast, the various DLD-1-derived cell lines showed little dierence in amount of JNK activity (Figure 3b ). DK03 and DKs8, which lack expression of KRas(13D), showed the same level of JNK as the parental DLD-1 line and the variant that retained KRas(13D) expression (DKs5). Thus, activation of JNK correlated with the expression of oncogenic Ras in HT1080, but not DLD-1, cells. We also did not detect appreciable dierences in p38 MAPK activity in any of the cell lines (data not shown).
Activation of Raf/MEK/ERK and JNK pathways in HT1080 cells resulted in constitutive activation of the TCF/Elk-1 transcription factor
The ERK and JNK MAPKs are activators of various nuclear transcription factors. For example, ERK causes phosphorylation and activation of Elk-1 (Marais et al., 1993) , and JNK phosphorylates and activates Elk-1 and Jun (Whitmarsh et al., 1995) . To determine whether the level of ERK and JNK activation correlated with enhanced activation Elk-1, we performed transient expression assays using the various HT1080 and DLD-1 cell lines. An expression plasmid that encodes a chimeric Gal-Elk-1 protein containing the DNA binding domain of the yeast Gal4 protein fused to the transactivation domain of Elk-1 was cotransfected with a reporter construct where luciferase gene expression was controlled by a promoter containing tandem Gal4 DNA binding sites.
Parental HT10806TG cells showed a threefold higher level of Elk-1 activity than that seen with MCH603c8 (Figure 4) . Consistent with the kinase assays, the N-ras(61K) transfectants of MCH603c8 showed elevated levels of Elk-1 activity that were higher than those seen for HT10806TG. Transient expression of exogenously introduced N-ras(61K) resulted in twofold activation of Elk-1 in MCH 603c8, whereas Elk-1 activity was not elevated further by the additional expression of N-Ras(61K) in cells that already possessed oncogenic N-Ras(61K) expression (data not shown). Thus, we found that Elk-1 activation correlated with the elevated ERK and JNK activity seen in oncogenic N-Ras(61K)-expressing versions of HT1080 cells. Use of a similar Gal-Jun chimeric expression construct with a Gal4-luciferase reporter also resulted in reduced c-Jun activation in MCH603c8 cells as compared to HT1080; re-expression of mutant N-Ras (61K) in MCH603c8 cells restored elevated Jun activity (data not shown).
In contrast to HT1080, there was no correlation between Elk-1 activity and K-ras(13D) mutation status in DLD-1 cell lines (Figure 4) . In fact, the highest activity was seen in the DKs8 knockout cell line that had lost the mutated K-ras(13D) allele. Therefore, consistent with what we observed in the ERK and JNK kinase assays, K-Ras(13D) expression did not correlate with increased Elk-1 activity. Figure 4 Increased Elk-1 activity is correlated with expression of activated Ras in HT1080, but not DLD-1 cells. HT1080-and DLD-1-derived cells were cotransfected with the pMMLV-Gal-Elk fusion construct together with a 56-Gal-Luc reporter. Luciferase activity was normalized to protein concentration using Lowry DC (Biorad). Luciferase activity was expressed as a percentage of the luciferase activity obtained after the simultaneous transfection with pGL2, a control construct which contains a SV40 promoter upstream of a luciferase gene. Fold activation was determined by comparing activities from HT1080-derived and DLD-1 derived cell lines to each parental cell line, respectively. Luciferase assays were performed in triplicate, in multiple independent assays (3 ± 5 times) using independent preparations of DNA with similar results
Transient overexpression of K-Ras(13D) causes activation of ERK2 in DLD-1 cells
The lack of MAPK upregulation in K-Ras(13D)-expressing cells argues that Ras-mediated transformation is promoted by upregulation of other signaling pathways in DLD-1 cells. However, there is evidence that the K-Ras(13D) mutant protein is not as potent as other activated forms of K-Ras. For example, 13D mutations are observed in colonic tumors from individuals who develop cancer at a later age (Perucho, unpublished observation) . In addition, KRas(13D) exhibits a much weaker transforming activity than K-Ras(12V) when expressed in rodent ®broblasts (Perucho, unpublished observations) . Thus, our observed lack of MAPK upregulation associated with expression of K-Ras(13D) may simply re¯ect the possibility that this activated mutant is not as potent as other activated K-Ras proteins in causing ERK activation. To evaluate this possibility, we compared the ability of dierent activated forms of K-Ras4B to cause activation of ERK in DLD-1 cells.
For these analyses, we utilized expression plasmids where wild type (13G) and mutant K-Ras4B proteins were expressed from the human genomic K-ras promoter (Winter and Perucho, 1986) . Mutant proteins included the weakly transforming 13D protein, as well as the highly transforming mutants harboring substitutions at residue 12 (12C, 12D and 12V). This approach was chosen to minimize overexpression of the exogenously introduced gene sequences. Transient expression of wild type K-Ras4B (13G) or vector DNA did not cause activation of cotransfected HA-ERK2 ( Figure 5 , data not shown). In contrast, expression of all four mutant K-Ras proteins in the parental DLD-1 cells led to HA-ERK2 activation. Essentially identical results were seen when the mutant proteins were expressed in wild type allele-de®cient DLD-1 cells (data not shown). We also observed that all mutant K-Ras proteins showed similar activation of Elk-1 in DKs8 cells (Figure 5b ). Taken together, these results suggest that the failure of K-Ras(13D)-expressing cells to cause MAPK upregulation is not due to an inherent defect of signaling in this pathway.
Suppression of the Raf/MEK/ERK pathway caused morphologic reversion of HT1080 ®brosarcoma cells and restoration of actin ®laments
Our observation that the Raf/MEK/ERK pathway was constitutively activated in ®brosarcoma cells that expressed the oncogenic N-ras(61K) allele suggests that upregulation of this kinase cascade may be necessary for N-Ras(61K)-mediated transformation of HT1080 cells. To evaluate this possibility, we utilized the PD098059 MEK inhibitor, which has been shown to speci®cally block ERK, but not JNK or p38, activation (Alessi et al., 1995) .
We ®rst determined whether treatment with PD098059 could eectively reduce ERK activation in HT1080. Serum-starved cultures were treated overnight with dierent concentrations of inhibitor and the level of ERK activation was then determined. Signi®cant reductions in both activated p42 and p44 ERKs were seen when HT1080 cells were treated with 20 mM PD098059 (Figure 6 ). At 75 mM, only a low level of Figure 5 All mutant forms of K-Ras4B cause activation of ERK. Mini-genomic mutant (12C, 12D, 12V, 13D) and wild type (13G) K-ras constructs, where expression is regulated by the human K-ras promoter, were transiently cotransfected in DK01 cells together with HA epitope-tagged ERK (HA-ERK2). HA-ERK2 phosphorylation was assessed by direct Western blot mobility shift assay using an anti-HA epitope antibody (a). Minigenomic wild type, or mutant K-ras constructs, or vector alone (300 ng) were transiently cotransfected with pMMLV-Gal-Elk fusion construct (250 ng) and 56Gal-Luc (2.5 mg) reporter into DKs8 cells (b). Luciferase activity was standardized to protein concentration using Lowry DC (Biorad). The assays were performed in triplicate, multiple times (3 ± 5), using dierent lots of K-Ras expression vector DNA with similar results Figure 6 Treatment with the PD098059 MEK inhibitor causes reduction of constitutive ERK phosphorylation in parental HT1080 but not DLD-1 cells. The indicated cells were serum-starved and treated overnight with the indicated concentration of PD098059. The cells were lysed and Western blot analysis was performed using the anti-active ERK antibody (Promega) activated p42 was detected in HT1080 or H-Ras(61L)-transformed NIH3T3 cells. Western blot analyses of total ERK expression in the treated cells con®rmed that the reduction in activated ERKs was not due to reduced levels of ERK expression (data not shown).
The low level of activated p42 ERK2 activity present in DLD-1 cells was not detectably reduced by treatment with up to 75 mM PD098059. Similarly, only modest (30%) reduction of ERK activation was seen in MCH603c8 cells treated with 50 mM PD098059. Therefore, both DLD-1 and MCH603c8 may possess MEK-independent activation of ERKs. Alternatively, MEK inhibition may not be complete even at high concentrations of inhibitor.
Treatment of parental HT10806TG cells with PD098059 caused a dramatic change in morphology (Figure 7) . The cells exhibited a more adherent appearance after treatment with as little as 20 mM of PD098059. When treated with 50 mM of inhibitor, HT10806TG cells were indistinguishable in appearance from untreated MCH603c8 cells. Thus, inhibition of ERK activation mimicked the loss of oncogenic Ras expression in HT1080 cells. Interestingly, treatment of MCH603c8 with PD098059 also caused additional attening (Figure 7k ), whereas treatment of DLD-1-derived cells had little eect on morphology ( Figure  7i ± l) .
We have shown previously that loss of the mutated N-ras allele caused an appearance of well organized actin stress ®bers in MCH603c8 cells (Plattner et al., 1996) . Therefore, we determined whether blocking ERK activation alone could similarly restore actin stress ®ber formation. Treatment of HT10806TG with PD098059 caused dose-dependent enhancement in the actin ®bers, with the appearance of organized stress ®bers similar to those seen in untreated MCH603c8 cells (Figure 7) . Interestingly, treatment of MCH603c8 cells caused a change in the appearance of its actin ®bers into prominent cable-like ®bers which were obvious at low drug concentrations (35 mM) and were striking at higher drug concentrations (75 mM) ( Figure  7h ). It is possible that the PD098059 inhibitor may have eects on cytoskeletal architecture unrelated to inhibition of MEK activity. We, therefore, stably transfected HT1080 cells with the MEK dominant negative expression vector, MEK-KA. Clones expressing MEK-KA had signi®cantly decreased ERK activity, approximating that of MCH603c8 (data not shown), and exhibited the reappearance of actin ®bers (Figure 8 ). Figure 7 Treatment of HT10806TG causes a reversion in morphology and actin ®lament organization similar to that seen with loss of N-Ras(61K) expression. HT10806TG (a ± d) and MCH 603c8 (e ± h) cells were treated for two days either with DMSO alone (a, b, e and f) or with 50 mM (c and d) or 75 mM (g and h) PD098059. Changes in cell morphology were visualized with phase contrast microscopy (506magni®cation). Actin organization was visualized by staining with Texas Redphalloidin and viewed with¯uorescence using Texas-Red excitation/emission ®lters (2006magni®cation), and CCD camera imaging (Oncor). The experiment was performed three times using various additional concentrations of MEK inhibitor (data not shown). Treatment of DLD-1-derived cell lines with PD098059 has little eect on cellular morphology; DLD-1 (i and j) and DKs8 (k and l) cells were treated either with DMSO alone (i and k) or with 50 mM PD098059 (j and l), and cellular morphology was visualized with phase-contrast microscopy (506magni®cation) 
Discussion
The importance of the Raf/MEK/ERK pathway in mediating Ras transformation of human tumor cells remains unresolved (Khosravi-Far et al., 1998) . Experimental studies using rodent ®broblast or epithelial cells have reached con¯icting conclusions. Furthermore, it is unclear whether the observations from these studies provide a valid assessment of the importance of this kinase cascade in promoting the Ras-induced transformed and tumorigenic phenotype in human tumor cells. Finally, whereas N-ras and Kras are most frequently mutated in human cancers, much of our knowledge on Ras signaling and transformation has been derived from studies using H-Ras-transformed cells (Clark and Der, 1993) . In the present study, we utilized two human tumor cell systems, where the contribution of oncogenic Ras to transformation has been established, in order to evaluate the role of the ERK and JNK pathways in cellular transformation. Parental and variant populations of HT1080 human ®brosarcoma and DLD-1 human colon carcinoma cells that dier in their Ras mutation status were evaluated (Plattner et al., 1996; Shirasawa et al., 1993) . Whereas the expression of mutated N-Ras(61K) correlated with constitutive upregulation of the Raf/MEK/ERK and JNK pathways in HT1080 cells, no such correlation was observed for the expression of mutated K-Ras(13D) in DLD-1 cells. Additionally, we found that inhibition of ERK activation caused a reversion of the transformed phenotype of HT1080 cells. Taken together, our observations suggest that constitutive Raf/MEK/ERK and JNK pathway activation is necessary for maintenance of the full transformed phenotype of HT1080 but not DLD-1 cells.
Our results with HT1080 ®brosarcoma cells are similar to observations with Ras-transformed NIH3T3 rodent ®broblasts (Khosravi-Far et al., 1995) . Oncogenic Ras activation of the Raf/MEK/ERK pathway has been shown to be necessary and sucient to cause growth and morphologic transformation of NIH3T3 cells (Cowley et al., 1994; Kolch et al., 1991; Mansour et al., 1994; Meloche et al., 1992; Westwick et al., 1994) . We found that constitutive activation of Raf, MEK and ERKs correlated with the expression of activated N-Ras in HT1080 cells. Whereas the loss of N-Ras(61K) expression in MCH603c8 cells corresponded to a decreased activation of the Raf/MEK/ ERK pathway, reintroduction of N-Ras(61K) expression caused restoration of upregulated activation of this kinase cascade. Inhibition of ERK activation in HT1080 cells by treatment with a MEK inhibitor caused the same reversion of cellular morphology and actin organization that was associated with loss of NRas(61K) expression in MCH603c8 cells. The same restoration of actin micro®laments was seen in HT1080 cells stably transfected with the MEK-KA dominant negative plasmid. Signi®cant decreases in p42 and p44 ERK activities accompanied expression of this dominant-negative MEK cDNA. These results suggest that the Raf/MEK/ERK pathway is a key mediator of at least some aspects of the transformed phenotype caused by oncogenic Ras in HT1080 cells.
Although Ras activation of Raf alone is sucient to cause transformation of NIH3T3 cells (Stokoe et al., 1994) , Ras eector domain mutants that are impaired in Raf binding can still cause tumorigenic transformation of NIH3T3 cells. Thus, Ras transformation of NIH3T3 cells is mediated by activation of both Rafdependent and Raf-independent eector pathways (Graham et al., 1996; Khosravi-Far et al., 1996; White et al., 1995) . At present, it is unclear whether activation of the Raf/MEK/ERK pathway alone is sucient for oncogenic Ras-mediated transformation of HT1080 cells. However, we have preliminary observations that overexpression of constitutively activated mutants of Raf-1 (Raf/CAAX and Raf22W) failed to restore tumorigenic growth potential to the oncogenic Rasde®cient MCH603c8 cells (Gupta, unpublished observations). Therefore, we anticipate that Ras activation of both Raf-dependent and Raf-independent pathways will be important for oncogenic Ras transformation of HT1080 cells. Ras causes activation of JNK via a Raf-independent pathway (Minden et al., 1994; Olson et al., 1995) . Inhibition of JNK activation has been shown to block Ras transformation of NIH3T3 cells (Clark et al., 1997) . Whether JNK activation is also important for Ras transformation of HT1080 cells will be important to determine.
In contrast to our observations with HT1080 cells, we found that expression of oncogenic K-Ras(13D) did not correlate with an upregulation of either ERKs or JNKs. These results suggest that upregulation of MAPKs is not required for Ras transformation of DLD-1 cells. Thus, we suggest that K-Ras might upregulate other eector-mediated pathways that promote growth transformation of these epithelial cells. This may well include the PI3-K pathway or, indeed, one or more as yet unidenti®ed pathways. We are currently examining these possibilities. Although it is possible that the lack of upregulation of MAPKs may re¯ect the weaker potency of the oncogenic KRas(13D) protein, we found that this mutant could cause a transient upregulation of ERKs that was comparable to that caused by more potent forms of oncogenic K-Ras4B protein (12D, 12V and 12C). Furthermore, we have found that overexpression of K-Ras(12V) under the control of a strong CMV promoter had a similar ability to activate ERK and Elk-1 as N-Ras(61K) (data not shown). Therefore, we do not believe that the lack of a correlation between the expression of oncogenic K-Ras(13D) and upregulation of MAPKs is due to dierences in signaling between N-Ras and K-Ras4B. Instead, we believe that this re¯ects cell type dierences in the signaling pathways that Ras utilizes to cause transformation of the ®broblastic HT1080 and the epithelial cell-derived DLD-1 cells. This possibility is consistent with our recent observations that Ras transformation of NIH3T3 mouse ®broblasts and RIE-1 rat epithelial cells is mediated by the activation of very distinct signaling pathways (Gangarosa et al., 1997; Oldham et al., 1996 Oldham et al., , 1998 .
In summary, our analyses of HT1080 and DLD-1 cells provide the ®rst evaluation of the contribution of MAPKs to oncogenic Ras transformation of human tumor cells. The lack of a correlation between the expression of oncogenic Ras and upregulation of MAPKs seen in DLD-1 cells argues that cell type dierences will exist regarding the signaling pathways that promote Ras transformation. Establishing the importance of MAPK pathways in promoting oncogenic Ras transformation of human tumor cells is important in light of the intense drug discovery eorts to develop inhibitors of these kinase cascades as novel anti-cancer agents. Our study suggests that upregulated MAPKs will be important for some, but not all, Ras mutation positive cancers. Further evaluation of the importance of the ERK and JNK pathways in human tumors where Ras mutations are frequently seen (e.g., lung, colon, and pancreatic carcinomas) will be required to further clarify whether upregulation of these pathways are cell-type speci®c as our data suggest. More studies such as this clearly are warranted before anti-ERK or other anti-Ras pathway therapies can be considered as potential cancer treatments.
Material and methods
Molecular constructs
The mammalian expression construct pCMVneo-Nras(61K) encodes an oncogenic form of N-Ras(61K) and was generated and characterized previously (Plattner et al., 1996) . Mini-genomic expression constructs that encode wild type (pMLG13) or mutant human K-Ras4B (pMLC12, pMLD12, pMLV12, and pMLD13 encode proteins with 12C, 12D, 12V and 13D mutations, respectively), where expression is controlled from the human K-ras promoter, have been described (Winter and Perucho, 1986; Perucho, manuscript in preparation) . The pLNCMKEA plasmid (provided by M Weber) encodes a hemagglutinin (HA) epitope-tagged ERK2 protein (Reuter et al., 1995) . The MEK-KA (104A) plasmid is a MEK dominant-negative construct that is mutated in the ATPbinding site. Plasmids for use in luciferase reporter assays (5X-Gal-Luc and pMMLV-Gal-Elk) were obtained from M Karin and R Treisman, respectively. The 5X-Gal-Luc construct contains ®ve yeast Gal4 DNA binding sites in a minimal promoter that controls expression of the luciferase gene. The pMMLV-Gal-Elk construct encodes a fusion protein where the Elk-1 DNA binding domain is replaced by the DNA binding domain of the yeast Gal4 protein (Marais et al., 1993) . The pGL2 control expression plasmid contains the luciferase gene under control of the constitutive SV40 promoter (Clontech).
Cell culture
The HT1080 cell line contains one wild type and one oncogenic (Q61K) N-ras allele (Anderson et al., 1994; Plattner et al., 1996) . The microcell hybrid cell line MCH603c8 was produced from HT10806TG by microcell-mediated chromosome transfer of a copy of an HT1080-derived chromosome 1 containing the wild type allele of N-ras. At some point subsequent to the transfer, the endogenous p-arm of chromosome 1 containing the mutant allele of N-ras was deleted (Anderson et al., 1994) . Thus, MCH603c8 contains two wild type N-ras alleles and no oncogenic N-ras allele. M5-8, M8-10, and M8-17 represent clonal isolates of MCH 603c8 cells that were stably transfected to re-establish expression of N-Ras(61K) and have been characterized previously (Plattner et al., 1996) . The DLD-1 human colon carcinoma cell line contains one oncogenic (G13D) and one wild type allele of K-ras (Shirasawa et al., 1993) . Variant clones where either the mutant (DK03, Dks8) or wild type (DK01) K-ras allele was inactivated by homologous recombination have been characterized and described previously. DKs5 represents a DLD-1 variant that was isolated during the homologous recombination procedure where both wild type and mutant K-ras alleles were retained. NIH3T3 cells transformed by overexpression of activated H-Ras(61L) have been described previously (Khosravi-Far et al., 1995) .
The parental HT10806TG cell line and all DLD-1-derived cells were maintained in Dulbecco's modi®ed Eagle's medium (DMEM) supplemented with 10% fetal calf serum (FCS) (gibco/BRL), whereas parental and Ras-transformed NIH3T3 cells were grown in DMEM supplemented with 10% calf serum (Hyclone). MCH603c8 was grown in growth medium supplemented with HAT (hypoxanthine/thymidine/methotrexate) (Plattner et al., 1996) . MCH603c8 variants stably transfected with an exogenous N-ras(61K) gene (M5-8, M8-10, and M8-17) were maintained in growth medium supplemented with HAT and 600 mg/ml G418 (Geneticin, gibco/BRL). MCH603c8 and transfected variants were weaned o of HAT selection prior to analysis as described previously (Plattner et al., 1996) .
Luciferase reporter assays
To measure Elk-1 activation, cells were transiently transfected by liposome-mediated transfection (lipofectin, Gibco/BRL) for 6 h with 2.5 mg of 56Gal-Luc reporter and 0.25 mg of the pMMLV-Gal-Elk expression constructs. The pGL2 plasmid (2.5 mg) was transfected to control for dierences in transfection eciencies between cell lines. After transfection, cells were serum-starved by incubation overnight in DMEM containing 0.25% serum, and lysed 24 h later in 16Cell Lysis reagent (Promega). The lysate was analysed for luciferase activity (Moonlight 2010 luminometer; Analytical Luminescence Laboratory) and normalized for protein concentration (Lowry DC reagent; Biorad).
ERK expression, activation, and inhibition analyses
Subcon¯uent (40 ± 60%) cultures were serum-starved for 24 h followed by either no stimulation or stimulation with epidermal growth factor (EGF) (10 ng/ml for 5 min at 378C). Stimulated and unstimulated cells were lysed in modi®ed RIPA buer #1 containing 50 mM Tris-HCl (pH 7.4), 1% NP-40, 0.25% sodium deoxycholate, 150 mM sodium chloride, 1 mM EGTA, 1 mM sodium orthovanadate, 1 mM sodium¯uoride, and phosphatase inhibitors (1 mM PMSF, 10 mg/ml aprotinin, leupeptin, pepstatin). Ten mg of total cell extracts was resolved on 8% sodium dodecyl sulfate polyacrylamide gels (SDS ± PAGE) and transferred onto Immobilon membranes (Millipore).
For endogenous ERK mobility shift assays, blots were incubated with the ERK-1 (sc-94, Santa Cruz Biotech) primary antibody which recognizes phosphorylated (active) and unphosphorylated (inactive) forms of the p44 ERK1 and p42 ERK2 proteins, followed by horseradish peroxidaseconjugated (HRP) goat anti-rabbit IgG secondary antibody (Santa Cruz Biotech) and chemiluminescence detection (Pierce).
To assay the eect of the dierent K-Ras4B mutants on HA-ERK2 phosphorylation, cells were transiently transfected with 2 mg of either a vector, wild type or mutant K-ras construct together with 2 mg of HA-ERK2 using liposomemediated transfection. Cells were serum-starved, lysed, and resolved on 8% SDS ± PAGE gels as above. Immobilon membranes were incubated with an anti-HA epitope monoclonal primary antibody (Babco) followed by antimouse IgG-HRP (Santa Cruz Biotech), secondary antibody, and chemiluminescence detection.
In order to assess the phosphorylation state of ERK proteins, antibodies speci®c for the phosphorylated forms of the ERK proteins (phosphospeci®c MAPK antibody (New England Biolabs), anti-active MAPK antibody (Promega) also were utilized.
To determine the contribution of ERK activation to transformation, we blocked ERK activation by using the PD098059 MEK inhibitor. This inhibitor has been shown to speci®cally block ERK, but not JNK or p38 activation (Alessi et al., 1995) . PD098059 (New England Biolabs) was dissolved in dimethylsulfoxide (DMSO). Two days after plating, cells were serum-starved overnight in medium containing various concentrations of PD098059. Control cultures, treated with only DMSO, were also included. The next day, the cells were lysed and Western blots were performed using anti-active MAPK antibody (Promega). To further analyse the contribution of MEK activation, a dominant-negative MEK (MEK-104A) plasmid was transfected as previously described (Plattner et al., 1996) . Multiple clonal populations were isolated and inhibition of ERK activity was assessed by Western blot analysis as described above.
Kinase assays
Kinase assays were performed as described previously (Graham et al., 1996) on serum-starved cultures of HT1080 and DLD-1-derived cell lines. Raf-1, MEK, or ERK was immunoprecipitated with anti-Raf-1 rabbit polyclonal antibody (C-12; Santa Cruz Biotech), MEK1 mouse monoclonal antibody (Transduction Laboratories) or anti-ERK1 rabbit polyclonal antibody (C16; Santa Cruz Biotech), respectively. The Raf-1 immunocomplex assay was carried out in a coupled assay using MEK as an intermediate (Reuter et al., 1995) . The MEK immunocomplex assay was carried out by incubating immunoprecipitated MEK with 5 mg of kinase-de®cient ERK protein for 30 min in the kinase reaction mix. The ERK immunocomplex assay was carried out by incubating immunoprecipitated ERK with 4 mg of myelin basic protein in a kinase assay for 20 min at 308C.
For JNK activation assays, lysates containing approximately 30 mg of proteins were incubated for 4 h with 1 ± 5 mg of GST-c-Jun (1 ± 79) to pull down JNK as described previously (Westwick and Brenner, 1995) . Alternatively, JNK was immunoprecipitated with JNK antibody (C17; Santa Cruz Biotech), and incubated in a kinase reaction with 2 mg of puri®ed GST-cJun. All kinase reactions were stopped by addition of 26SDS ± PAGE sample buer. Proteins were separated on 15% SDS ± PAGE and visualized by autoradiography.
Actin cytoskeleton staining
Actin stress ®bers were visualized by staining with Texas Red-conjugated phalloidin (Molecular Probes). Two days after plating, cells were treated with PD098059, an inhibitor of MEK activity (Alessi et al., 1995) , for 2 days at various concentrations, or incubated with an equivalent amount of DMSO alone. Cells were ®xed in 3.7% paraformaldehyde, stained with phalloidin (0.005 U/ml) for 20 min at room temperature, and mounted in Prolong Fade antifade (Molecular Probes). Clones that had been stably transfected with the MEK dominant negative plasmid were processed in a similar fashion.
